Stevens Robert D, Dowdy David W, Michaels Robert K, Mendez-Tellez Pedro A, Pronovost Peter J, Needham Dale M
Department of Anesthesiology/Critical Care Medicine, Johns Hopkins University School of Medicine, 600 N Wolfe St, Meyer 8-140, Baltimore, MD 21287, USA.
Intensive Care Med. 2007 Nov;33(11):1876-91. doi: 10.1007/s00134-007-0772-2. Epub 2007 Jul 17.
To determine the prevalence, risk factors, and outcomes of critical illness neuromuscular abnormalities (CINMA).
Systematic review.
MEDLINE, EMBASE, CINAHL, and the Cochrane Library were searched for reports on adult ICU patients who were evaluated for CINMA clinically and electrophysiologically. Studies were included if they contained sufficient data to quantify the association between CINMA and relevant exposures and/or outcome variables.
CINMA was diagnosed in 655 of 1421 [46% (95% confidence interval 43-49%)] adult ICU patients enrolled in 24 studies, all with inclusion criteria of sepsis, multi-organ failure, or prolonged mechanical ventilation. Diagnostic criteria for CINMA were not uniform, and few reports unequivocally differentiated between polyneuropathy, myopathy, and mixed types of CINMA. The risk of CINMA was associated with hyperglycemia (and inversely associated with tight glycemic control), the systemic inflammatory response syndrome, sepsis, multiple organ dysfunction, renal replacement therapy, and catecholamine administration. Across studies, there was no consistent relationship between CINMA and patient age, gender, severity of illness, or use of glucocorticoids, neuromuscular blockers, aminoglycosides, or midazolam. Unadjusted mortality was not increased in the majority of patients with CINMA, but mechanical ventilation and ICU and hospital stay were prolonged.
The risk of CINMA is nearly 50% in ICU patients with sepsis, multi-organ failure, or protracted mechanical ventilation. The association of CINMA with frequently cited CINMA risk factors (glucocorticoids, neuromuscular blockers) and with short-term survival is uncertain. Available data indicate glycemic control as a potential strategy to decrease CINMA risk.
确定危重症性神经肌肉异常(CINMA)的患病率、危险因素及预后。
系统评价。
检索MEDLINE、EMBASE、CINAHL和Cochrane图书馆,查找关于对成年ICU患者进行CINMA临床和电生理评估的报告。若研究包含足够数据以量化CINMA与相关暴露因素和/或结局变量之间的关联,则纳入研究。
在纳入24项研究的1421例成年ICU患者中,655例(46%[95%置信区间43 - 49%])被诊断为CINMA,所有患者均符合脓毒症、多器官功能衰竭或长时间机械通气的纳入标准。CINMA的诊断标准并不统一,很少有报告能明确区分多神经病、肌病及混合型CINMA。CINMA的风险与高血糖相关(与严格血糖控制呈负相关)、全身炎症反应综合征、脓毒症、多器官功能障碍、肾脏替代治疗及儿茶酚胺的使用有关。在各项研究中,CINMA与患者年龄、性别、疾病严重程度或糖皮质激素、神经肌肉阻滞剂、氨基糖苷类药物或咪达唑仑的使用之间没有一致的关系。大多数CINMA患者的未调整死亡率并未增加,但机械通气时间、ICU住院时间和住院时间延长。
在患有脓毒症、多器官功能衰竭或长期机械通气的ICU患者中,CINMA的风险接近50%。CINMA与经常提及的CINMA危险因素(糖皮质激素、神经肌肉阻滞剂)及短期生存之间的关联尚不确定。现有数据表明血糖控制是降低CINMA风险的一种潜在策略。